Haleon plc (NYSE:HLN) Position Boosted by Principal Securities Inc.

Principal Securities Inc. raised its holdings in shares of Haleon plc (NYSE:HLN) by 46.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,878 shares of the company’s stock after acquiring an additional 24,997 shares during the quarter. Principal Securities Inc.’s holdings in Haleon were worth $752,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of HLN. Fortitude Family Office LLC bought a new stake in shares of Haleon in the 3rd quarter valued at approximately $28,000. Versant Capital Management Inc lifted its holdings in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Haleon in the 4th quarter worth approximately $35,000. Toronto Dominion Bank lifted its holdings in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in Haleon in the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Down 1.0 %

Shares of HLN stock opened at $9.89 on Friday. The stock has a 50 day moving average of $9.55 and a 200-day moving average of $9.82. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $44.75 billion, a PE ratio of 29.07, a price-to-earnings-growth ratio of 2.84 and a beta of 0.28. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HLN shares. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.